• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,054.24 +17.09 (+1.65%)
    Streaming Delayed Price Updated: 12:14 PM EST, Feb 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    VenHub Appoints Former Amazon Executive, Ian Rasmussen, to Spearhead Nationwide Smart Store Expansion with Focus on Strategic Partnerships and Enterprise Integrations
    VenHub Global, Inc. (NASDAQ:VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced the appointment of Ian Rasmussen as 
    Via PressReach
    News headline image
    3 Headwinds Facing Pfizer in 2026 ↗
    Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Where Will AbbVie Be in 5 Years? ↗
    A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier. 
    Via The Motley Fool
    Topics Intellectual Property
    Eli Lilly & Co (NYSE:LLY) Emerges as a Top GARP Investment Candidate ↗
    Via Chartmill
    News headline image
    Commodity Volatility, Earnings and Other Key Things to Watch
    Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee. 
    Via Barchart.com
    Topics Economy
    News headline image
    Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? ↗
    This could finally be the start of the drugmaker's comeback. 
    Via The Motley Fool
    News headline image
    Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill ↗
    Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a game-changer for the launch of its experimental weight-loss pill orforglipron, potentially expanding access to... 
    Via Benzinga
    News headline image
    Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report ↗
    CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk. 
    Via Stocktwits
    Topics Government
    News headline image
    Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? ↗
    Novo Nordisk's weight loss pill could give the company's numbers a big boost this year. 
    Via The Motley Fool
    News headline image
    Stock Yards Bank Buys $25 Million of Stock Yards Bancorp Stock ↗
    Stock Yards Bancorp delivers commercial banking and wealth management services across key Midwest metropolitan markets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases ↗
    Novo Nordisk sharply increased U.S. advertising for Wegovy and Ozempic in 2025, outspending Eli Lilly as competition for obesity drugs intensified. 
    Via Benzinga
    News headline image
    FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock? ↗
    The target action date for orforglipron is now April 10. 
    Via The Motley Fool
    News headline image
    Should You Buy Eli Lilly Before Feb. 4? ↗
    Is there another beat-and-raise in the pharmaceutical giant's near future? 
    Via The Motley Fool
    News headline image
    Should You Buy Guardant Health Before Feb. 19? ↗
    This genomics stock appears to be at an inflection point. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion ↗
    Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease treatments and gene therapies targeting hearing loss. 
    Via Benzinga
    News headline image
    How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity ↗
    Roche hopes to rival Eli Lilly and Novo Nordisk in the weight-loss space. 
    Via Investor's Business Daily
    News headline image
    Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead. ↗
    This pharmaceutical giant is increasingly looking unstoppable. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Can This Beaten-Down AI Stock Bounce Back in 2026? ↗
    It might take a while for this AI company to prove its worth, if it ever does so. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. ↗
    Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future. 
    Via The Motley Fool
    News headline image
    FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency
    In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial... 
    Via TokenRing AI
    Topics Artificial Intelligence Economy
    News headline image
    The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life
    In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic... 
    Via TokenRing AI
    Topics Artificial Intelligence Economy
    News headline image
    Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
    In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire... 
    Via MarketMinute
    News headline image
    Eli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing Loss ↗
    Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss. 
    Via Stocktwits
    Topics Economy Government
    News headline image
    Top Picks 2026: Eli Lilly & Co. ↗
    LLY is surging as its weight-loss duopoly remains a 2026 
    Via Talk Markets
    News headline image
    The Master Architect of Molecules: How Google DeepMind’s AlphaProteo is Rewriting the Blueprint for Cancer Therapy
    In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a... 
    Via TokenRing AI
    Topics Artificial Intelligence
    News headline image
    Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
    In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx... 
    Via MarketMinute
    News headline image
    1 Pharmaceutical Stock Set to Rebound in 2026 ↗
    Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026. 
    Via The Motley Fool
    News headline image
    Carvina Capital: Strong Demand Lifts Aktis IPO
    Via AB Newswire
    News headline image
    Up 36%, Is Eli Lilly Still a Buy? ↗
    Thanks to its weight loss and diabetes products, the drug company has seen its shares soar. 
    Via The Motley Fool
    News headline image
    Where Will Eli Lilly Be in 10 Years? ↗
    Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever. 
    Via The Motley Fool
    Topics ETFs Intellectual Property
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.